Cargando…
Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer
For nearly three decades, chimeric antigen receptors (CARs) have captivated the interest of researchers seeking to find novel immunotherapies to treat cancer. CARs were first designed to work with T cells, and the first CAR T cell therapy was approved to treat B cell lymphoma in 2017. Recent advance...
Autores principales: | Moreno, Carlos, Haynie, Christopher, Cheever, Abigail, Weber, K. Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313317/ https://www.ncbi.nlm.nih.gov/pubmed/35884798 http://dx.doi.org/10.3390/biomedicines10071493 |
Ejemplares similares
-
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
por: Keshavarz, Ali, et al.
Publicado: (2022) -
Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances
por: Nikoo, Marzieh, et al.
Publicado: (2022) -
Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies
por: Mangal, Joslyn L., et al.
Publicado: (2021) -
Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021) -
Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)